Codice QR

Anlotinib monotherapy in recurrent or metastatic nasopharyngeal carcinoma: a multicenter case-series analysis

Anlotinib has shown encouraging therapeutic effect on various solid tumors. This study assessed the efficacy and safety of anlotinib monotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma (rmNPC).

Salvato in:
Autori principali: Qin Guan-Jie, Su Yi-Xin, Liang Yong, Zhang Bin, Pan Yu-Fei, Lu Jian-Xun, Xie Yue-Yun, Dai Jin-Xuan, Chen Ke-Quan, Qin Feng-Fei, Yang Hui-Yun, Kong Xiang-Yun, Xie Yuan, Ruan Xiao-Lan, Mo Yun-Yan, Zhang Ru-Yun, Zhang Jian, Jiang Wei
Natura: Artigo
Lingua:Inglês
Pubblicazione: Sciendo 2025-12-01
Serie:Radiology and Oncology
Soggetti:
anlotinib
nasopharyngeal carcinoma
recurrent
metastasis
tyrosine kinase inhibitors (tki)
Accesso online:https://doi.org/10.2478/raon-2025-0059
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi